Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. Gangat N, Bleeker J, Lynch D, Olteanu H, et al. Haematologica 2022;107:2523-2526.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gangat N, Bleeker J, Lynch D, Olteanu H, et al. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. Haematologica 2022;107:2523-2526.
PMID: 35678030